Alentis Appoints Alberto Toso Chief Scientific Officer

Contributed by: Business Wire

Logo

Images

Alberto Toso, Chief Scientific Officer of Alentis Therapeutics (Photo: Alentis Therapeutics)

Business Wire embedded0

Tags

Oncology

Health

Other Health

Clinical Trials

Pharmaceutical

Biotechnology

Alberto Toso

More Like This

Dr. William Pao has joined Alentis Therapeutics' Board of Directors as an independent member. (Photo: Alentis Therapeutics)

William Pao Joins Alentis Therapeutics as Independent Board Member

Jon Freve, Chief Financial Officer of Alentis Therapeutics (Photo: Alentis Therapeutics)

Alentis Appoints Jonathan Freve CFO

Rizwan Velji has joined Alentis Therapeutics as Chief Business Officer (Photo: Alentis Therapeutics)

Alentis Therapeutics Expands Leadership Team with the Appointment of Rizwan Velji as Chief Business Officer

Alentis Therapeutics Raises $181.4 Million in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors

Alentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors

Tiziana Life Sciences Appoints New Chief Executive Officer

Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis

Alentis Therapeutics Doses First ANCA-Associated Vasculitis Rapidly Progressive Glomerulonephritis Patient in Phase 2 Clinical Trial of Lixudebart (ALE.F02)